SCHEMBL968396

SCHEMBL968396

CCN(CC)CCSCCO

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 2/20 0.37
ALDH2 P05091 1/20 0.37
HPGD P15428 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
ROCK2 O75116 1/20 0.32
SLC2A1 P11166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950901 0.87 SLC2A1 (0.37) ALDH1A1HPGDMAPTCHRM2CHRM4
SCHEMBL24299500 0.79 SLC2A1 (0.33) ALDH1A1HPGDMAPTCHRM2CHRM4
SCHEMBL950518 0.77 SLC2A1 (0.32) ALDH1A1HSD17B10MAPTCHRM2CHRM4
SCHEMBL7134219 0.77 TDP1 (0.45) TDP1ALDH1A1ALDH2HPGDCYP1A2
SCHEMBL5002428 0.76 MEN1 (0.34) MAPTCHRM2CHRM4CHRM1CHRM3
SCHEMBL11260442 0.75 CYP1A2 (0.32) CYP1A2MAPTSLC2A1
SCHEMBL20102190 0.75 TDP1 (0.50) TDP1
SCHEMBL6719978 0.74
SCHEMBL20102189 0.73 TDP1 (0.42) TDP1
SCHEMBL3823316 0.72 SLC2A1 (0.32) MAPTCHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872134-B2 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates TELIK, INC. (US) 2011-01-18 US disclosed
WO-2009076473-A1 2-{[2-(SUBSTITUTED AMINO)ETHYL]SULFONYL}ETHYL N,N-BIS(2- CHLOROETHYL)PHOSPHORODIAMIDATES TELIK, INC. (US) 2009-06-18 WO disclosed
US-20090156559-A1 2-ethyl N,N-bis(2-chloroethyl)phosphorodiamidates TELIK, INC. 2009-06-18 US disclosed
EP-0518352-B1 Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor DAINIPPON INK & CHEMICALS (JP) 1998-04-22 EP disclosed
US-5460919-A Process of forming super high-contrast negative images and silver halide photographic material and developer being used therefor DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-10-24 US disclosed
US-5372911-A Support having one or more hydrophilic colloidal layers, at least one layer contains pyridinium salt or derivative, quinolinium salt or derivative, or isoquinolinium salt or derivative DAINIPPON INK AND CHEMICALS, INC. (JP) 1994-12-13 US disclosed
EP-0518352-A1 Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor DAINIPPON INK AND CHEMICALS, INC. (JP) 1992-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156559-A1 2-ethyl N,N-bis(2-chloroethyl)phosphorodiamidates PHOSPHO1, SSB, BCL9 TDP1 1260/4885ALDH1A1 4690/4885ALDH2 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.